What’s in the pipeline? Drugs in development for autism spectrum disorder

References

• ChiappediMRossiGRossiMBejorMBalottinUAutism and classification systems: a study of 84 childrenItal J Pediatr20103610
   Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders5th edArlington, VAAmerican Psychiatric Publishing2013
   Google Scholar
• KumarBPrakashASewalRKMedhilBModiMDrug therapy in autism: a present and future perspectivePharmacol Rep20126461291130423406740
   PubMed Web of Science ®Google Scholar
• SungMFungDSSCaiYMOoiYPPharmacological management in children and adolescents with pervasive developmental disordersAust N Z J Psychiatry201044541042820047454
   PubMed Web of Science ®Google Scholar
• MaloneRPWaheedAThe role of antipsychotics in the management of behavioural symptoms in children and adolescents with autismDrugs2009695535548
   PubMed Web of Science ®Google Scholar
• CampbellMArmenterosJLMaloneRPAdamsPBEisenbergZWOverallJENeuroleptic-related dyskinesias in autistic children: a prospective, longitudinal studyJ Am Acad Child Adolesc Psychiatry1997366835843
   PubMed Web of Science ®Google Scholar
• McDougleCJStiglerKAEricksonCAPoseyDJAtypical antipsychotics in children and adolescents with autistic and other pervasive developmental disordersJ Clin Psychiatry200869Suppl 41520
   PubMed Web of Science ®Google Scholar
• PotenzaMNHolmesJPKanesSJMcDougleCJOlanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot studyJ Clin Psychopharmacol199919137449934941
   PubMed Web of Science ®Google Scholar
• MaloneRPCaterJSheikhRMChoudhuryMSDelaneyMAOlanzapine versus haloperidol in children with autistic disorder: an open pilot studyJ Am Acad Child Adolesc Psychiatry2001408887894
   PubMed Web of Science ®Google Scholar
• HollanderEWassermanSSwansonENA double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorderJ Child Adolesc Psychopharmacol200616554154817069543
   PubMed Web of Science ®Google Scholar
• FidoAAl-SaadSOlanzapine in the treatment of behavioral problems associated with autism: an open-label trial in KuwaitMed Princ Pract2008175415418
   PubMed Web of Science ®Google Scholar
• MartinAKoenigKScahillLBregmanJOpen-label quetiapine in the treatment of children and adolescents with autistic disorderJ Child Adolesc Psyschopharmacol19999299107
   PubMed Web of Science ®Google Scholar
• BlairJScahillLStateMMartinAElectrocardiographic changes in children and adolescents treated with ziprasidone: a prospective studyJ Am Acad Child Adolesc Psychiatry20054417379
   Web of Science ®Google Scholar
• CorrellCULopsJDFigenVMalhotraAKKaneJMManuPQT interval duration and dispersion in children and adolescents treated with ziprasidoneJ Clin Psychiatry2011726854860
   PubMed Web of Science ®Google Scholar
• MaloneRPDelaneyMAHymanSBCaterJRZiprasidone in adolescents with autism: an open-label pilot studyJ Child Adolesc Psychopharmacol2007176779790
   PubMed Web of Science ®Google Scholar
• De HertMDobbelaereMSheridanEMCohenDCorrellCUMetabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practiceEur Psychiatry2011263144158
   PubMed Web of Science ®Google Scholar
• CacciaSSafety and pharmacokinetics of atypical antipsychotics in children and adolescentsPaediatr Drugs2013153217233
   PubMed Web of Science ®Google Scholar
• McCrackenJTMcGoughJShahBResearch Units on Pediatric Psychopharmacology Autism NetworkRisperidone in children with autism and serious behavioral problemsN Engl J Med20023475314321
   PubMed Web of Science ®Google Scholar
• McDougleCJScahillLAmanMGRisperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric pharmacologyAm J Psychiatry2005162611421148
   PubMed Web of Science ®Google Scholar
• SheaSTurgayACarrollARisperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disordersPediatrics20041145e634e641
   PubMed Web of Science ®Google Scholar
• JesnerOSAref-AdibMCorenERisperidone for autism spectrum disorder [review]Cochrane Database Syst Rev20071CD005040
   Google Scholar
• SharmaAShawSREfficacy of risperidone in managing maladaptive behaviors in children with autistic spectrum disorder: a meta-analysisJ Pediatr Health Care2012264291299
   PubMed Web of Science ®Google Scholar
• LemmonMEGregasMJesteSSRisperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient populationJ Child Neurol2011264428432
   PubMed Web of Science ®Google Scholar
• KentJMKushnerSNingXRisperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled studyJ Autism Dev Disord201343817731783
   PubMed Web of Science ®Google Scholar
• MaayanLCorrellCUWeight gain and metabolic risks associated with antipsychotic medications in children and adolescentsJ Child Adolesc Psychopharmacol2011216517535
   PubMed Web of Science ®Google Scholar
• RezaeiVMohammadiMRGhanizadehADouble-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorderProg Neuropsychopharmacol Biol Psychiatry201034712691272
   PubMed Web of Science ®Google Scholar
• AkhondzadehSFallahJMohammadiMRDouble-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autismProg Neuropsychopharmacol Biol Psychiatry20103413236
   PubMed Web of Science ®Google Scholar
• GhaleihaAAsadabadiMMohammadiMRMemantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trialInt J Neuropsychopharmacol2013164783789
   PubMed Web of Science ®Google Scholar
• AsadabadiMMohammadiMRGhanizadehACelecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trialPsychopharmacology (Berl)201322515159
   PubMed Web of Science ®Google Scholar
• CurranMPAripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patientsPaediatr Drugs2011133197204
   PubMed Web of Science ®Google Scholar
• BlankenshipKEricksonCAStiglerKAPoseyDJMcDougleCJAripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 yearsPed Health201044375381
   Google Scholar
• OwenRSikichLMarcusRNAripiprazole in the treatment of irritability in children and adolescents with autistic disorderPediatrics200912461533154019948625
   PubMed Web of Science ®Google Scholar
• MarcusRNOwenRKamenLA placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorderJ Am Acad Child Adolesc Psychiatry2009481111101119
   PubMed Web of Science ®Google Scholar
• ChingHPringsheimTAripiprazole for autism spectrum disorders (ASD) [review]Cochrane Database Syst Rev20125CD009043
   PubMed Web of Science ®Google Scholar
• MarcusRNOwenRManosGAripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label studyJ Child Adolesc Psychopharmacol201121322923621663425
   PubMed Web of Science ®Google Scholar
• StiglerKADienerJTKohnAEAripiprazole in pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 14-week, prospective, open-label studyJ Child Adolesc Psychopharmacol2009193265274
   PubMed Web of Science ®Google Scholar
• MasiGCosenzaAMillepiediSMuratoriFPariCSalvadoriFAripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective studyCNS Drugs2009236511521
   PubMed Web of Science ®Google Scholar
• LambreySFalissardBMartin-BarreroMEffectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorderJ Child Adolesc Psychopharmacol20102017980
   PubMed Web of Science ®Google Scholar
• StiglerKAMullettJEEricksonCAPoseyDJMcDougleCJPaliperidone for irritability in adolescents and young adults with autistic disorderPsychopharmacology (Berl)20122232237245
   PubMed Web of Science ®Google Scholar
• StiglerKAEricksonCAMullettJEPoseyDJMcDougleCJPaliperidone for irritability in autistic disorderJ Child Adolesc Psychopharmacol20102017578
   PubMed Web of Science ®Google Scholar
• KowalskiJLWinkLKBlankenshipKPaliperidone palmitate in a child with autistic disorderJ Child Adolesc Psychopharmacol2011215491493
   Web of Science ®Google Scholar
• HollanderEPhillipsAChaplinWA placebo-controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autismNeuropsychopharmacology2005303582589
   PubMed Web of Science ®Google Scholar
• DeLongGRRitchCRBurchSFluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievementDev Med Child Neurol20024410652659
   Web of Science ®Google Scholar
• HollanderESooryaLChaplinWA double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disordersAm J Psychiatry20121693292299
   PubMed Web of Science ®Google Scholar
• SugieYSugieHFukudaTClinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autismJ Autism Dev Disord2005353377385
   PubMed Web of Science ®Google Scholar
• NamerowLThomasPBosticJQPrinceJMonuteauxMCUse of citalopram in pervasive developmental disordersJ Dev Behav Pediatr2003242104108
   PubMed Web of Science ®Google Scholar
• OwleyTWaltonLSaltJAn open-label trial of escitalopram in pervasive developmental disordersJ Am Acad Child Adolesc Psychiatry2005444343348
   PubMed Web of Science ®Google Scholar
• CarrascoMVolkmarFRBlochMHPharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication biasPediatrics20121295e1301e131022529279
   PubMed Web of Science ®Google Scholar
• WilliamsKWheelerDMSiloveNHazellPSelective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD) [review]Cochrane Database Syst Rev20108CD004677
   Google Scholar
• GordonCTStateRCNelsonJEHamburgerSDRapoportJLA double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorderArch Gen Psychiatry1993506441447
   PubMed Web of Science ®Google Scholar
• RemingtonGSlomanLKonstantareasMParkerKGowRClomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled crossover studyJ Clin Psychopharmacol2001214440444
   PubMed Web of Science ®Google Scholar
• HurwitzRBlackmoreRHazellPWilliamsKWoolfendenSTricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents [review]Cochrane Database Syst Rev20123CD008372
   Google Scholar
• WestLBrunssenSHWaldropJReview of the evidence for treatment of children with selective serotonin reuptake inhibitorsJ Spec Pediatr Nurse2009143183191
   Web of Science ®Google Scholar
• HollanderEChaplinWSooryaLDivalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disordersNeuropsychopharmacology2010354990998
   PubMed Web of Science ®Google Scholar
• HellingsJAWeckbaughMNickelEJA double-blind, placebo-controlled study of valproate for aggression in the youth with pervasive developmental disordersJ Child Adolesc Psychopharmacol2005154682692
   PubMed Web of Science ®Google Scholar
• HollanderESooryaLWassermanSEspositoKChaplinWAnagnostouEDivalproex sodium vs placebo in the treatment of repetitive behaviours in autism spectrum disorderInt J Neuropsychopharmacol200692209213
   PubMed Web of Science ®Google Scholar
• RuginoTASamsockTCLevetiracetam in autistic children: an open-label studyJ Dev Behav Pediatr2002234225230
   PubMed Web of Science ®Google Scholar
• WassermanSIyengarRChaplinWFLevetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled studyInt Clin Psychopharmacol2006216363367
   PubMed Web of Science ®Google Scholar
• SiegelMBeaulieuAAPsychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practiceJ Autism Dev Disord201242815921605
   Web of Science ®Google Scholar
• WilliamsonEDMartinAPsychotropic medications in autism: practical considerations for parentsJ Autism Dev Disord201242612491255
   Web of Science ®Google Scholar
• MillerNLFindlingRLIs methylphenidate a safe and effective treatment for ADHD-like symptoms in children with pervasive developmental disorders?Expert Opin Pharmacother20078710251028
   PubMed Web of Science ®Google Scholar
• GhumanJKAmanMGLecavalierLRandomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disordersJ Child Adolesc Psychopharmacol2009194329339
   PubMed Web of Science ®Google Scholar
• JahromiLBKasariCLMcCrackenJTPositive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivityJ Autism Dev Disord2009393395404
   PubMed Web of Science ®Google Scholar
• DavisNOKollinsSHTreatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorderNeurotherapeutics201293518530
   PubMed Web of Science ®Google Scholar
• QuintanaHBirmaherBStedgeDUse of methylphenidate in the treatment of children with autistic disorderJ Autism Dev Disord19952532832947559293
   PubMed Web of Science ®Google Scholar
• HandenBLJohnsonCRLubetskyMEfficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorderJ Autism Dev Disord200030324525511055460
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism NetworkRandomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivityArch Gen Psychiatry200562111266127416275814
   PubMed Web of Science ®Google Scholar
• BuitelaarJKDanckaertsMGillbergCStomoxetine International Study GroupA prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHDEur Child Adolesc Psychiatry2004134249257
   PubMed Web of Science ®Google Scholar
• GhanizadehAAtomoxetine for treating ADHD symptoms in autism: a systematic reviewJ Atten Disord2013178635640
   Web of Science ®Google Scholar
• CharnsilCEfficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label studyJ Atten Disord201115868468920686100
   PubMed Web of Science ®Google Scholar
• HarfterkampMvan de Loo-NeusGMinderaaRBA randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorderJ Am Acad Child Adolesc Psychiatry2012517733741
   PubMed Web of Science ®Google Scholar
• HarfterkampMBuitelaarJKMinderaaRBLong-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension studyJ Child Adolesc Psychopharmacol2013233194199
   PubMed Web of Science ®Google Scholar
• TroostPWSteenhuisMPTuynman-QuaHGAtomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot studyJ Child Adolesc Psychopharmacol200616561161917069549
   PubMed Web of Science ®Google Scholar
• ArnoldLEAmanMGCookAMAtomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trialJ Am Acad Child Adolesc Psychiatry200645101196120517003665
   PubMed Web of Science ®Google Scholar
• NiederhoferHDamodharanSKJojiRCorfieldAAtomoxetine treating patients with Autistic disorderAutism2006106647649
   Web of Science ®Google Scholar
• PoseyDJWiegandREWilkersonJMaynardMStiglerKAMcDougleCJOpen-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disordersJ Child Adolesc Psychopharmacol2006165599610
   PubMed Web of Science ®Google Scholar
• ZeinerPGjevikEWeidleBResponse to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorderActa Paediatr2011100912581261
   PubMed Web of Science ®Google Scholar
• PoseyDJPuntneyJISasherTMKemDLMcDougleCJGuanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 casesJ Child Adolesc Psychopharmacol2004142233241
   PubMed Web of Science ®Google Scholar
• ScahillLAmanMGMcDougleCJA prospective open trial of guanfacine in children with pervasive developmental disordersJ Child Adolesc Psychopharmacol2006165589598
   PubMed Web of Science ®Google Scholar
• HandenBLSahlRHardanAYGuanfacine in children with autism and/or intellectual disabilitiesJ Dev Behav Pediatr2008294303308
   PubMed Web of Science ®Google Scholar
• DavissWBPatelNCRobbASClonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysisJ Am Acad Child Adolesc Psychiatry2008472189198
   PubMed Web of Science ®Google Scholar
• JaselskisCACookEHJrFletcherKELeventhalBLClonidine treatment of hyperactive and impulsive children with autistic disorderJ Clin Psychopharmacol1992125322327
   PubMed Web of Science ®Google Scholar
• FankhauserMPKarumanchiVCGermanMLYatesAKarumanchiSDA double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autismJ Clin Psychiatry199253377821548248
   PubMed Web of Science ®Google Scholar
• PoseyDJEricksonCAMcDougleCJDeveloping drugs for core social and communication impairment in autismChild Adolesc Psychiatr Clin N Am2008174787801viiiix18775370
   PubMed Web of Science ®Google Scholar
• AndersenIMKaczmarskaJMcGrewSGMalowBAMelatonin for insomnia in children with autism spectrum disordersJ Child Neurol2008235482485
   PubMed Web of Science ®Google Scholar
• Galli-CarminatiGDeriazNBertschyGMelatonin in treatment of chronic sleep disorders in adults with autism: a retrospective studySwiss Med Wkly200913919–20292296
   Web of Science ®Google Scholar
• MalowBAdkinsKWMcGrewSGMelatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomesJ Autism Dev Disord201242817291737
   PubMed Web of Science ®Google Scholar
• WirojananJJacquemontSDiazRThe efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndromeJ Clin Sleep Med200952145150
   PubMed Web of Science ®Google Scholar
• WrightBSimsDSmartSMelatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trialJ Autism Dev Disord2011412175184
   PubMed Web of Science ®Google Scholar
• CortesiFGiannottiFSebastianiTPanunziSValenteDControlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trialJ Sleep Res2012216700709
   PubMed Web of Science ®Google Scholar
• FreemanMPHibbelnJRWisnerKLOmega-3 fatty acids: evidence basis for treatment and future research in psychiatryJ Clin Psychiatry2006671219541967
   PubMed Web of Science ®Google Scholar
• BentSBertoglioKHendrenRLOmega-3 fatty acids for autistic spectrum disorder: a systemic reviewJ Autism Dev Disord200939811451154
   PubMed Web of Science ®Google Scholar
• JamesSMontgomeryPWilliamsKOmega-3 fatty acids supplementation for autism spectrum disorders (ASD) [review]Cochrane Database Syst Rev201111CD00799222071839
   PubMed Web of Science ®Google Scholar
• FlashnerBMRussoMEBoileauJELeongDWGallicanoGIEpigenetic factors and autism spectrum disordersNeuromolecular Med2013152339350
   Web of Science ®Google Scholar
• ChaoHTChenHSamacoRCDysfunction in GABA signaling mediates autism-like stereotypies and Rett syndrome phenotypesNature20104687321263269
   PubMed Web of Science ®Google Scholar
• D’HulstCHeulensIBrouwerJRExpression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS)Brain Res20091253176183
   Web of Science ®Google Scholar
• EhningerDSilvaAJRapamycin for treating Tuberous sclerosis and Autism spectrum disordersTrends Mol Med20111727887
   PubMed Web of Science ®Google Scholar
• HussmanJPChungRHGriswoldAJA noise-reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autismMol Autism2011211
   Web of Science ®Google Scholar
• JacobSBruneCWBadnerJAFamily-based association testing of glutamate transporter genes in autismPsychiatr Genet2011214212213
   Web of Science ®Google Scholar
• FatemiSHReutimanTJFolsomTDThurasPDGABA(A) receptor downregulation in brains of subjects with autismJ Autism Dev Disord200939222323018821008
   PubMed Web of Science ®Google Scholar
• ShimmuraCSudaSTsuchiyaKJAlteration of plasma glutamate and glutamine levels in children with high-functioning autismPLoS One2011610e25340
   Web of Science ®Google Scholar
• Abu ShmaisGAAl-AyadhiLYAl-DbassAMEl-AnsaryAKMechanism of nitrogen metabolism-related parameters and enzyme activities in the pathophysiology of autismJ Neurodev Disord2012414
   Web of Science ®Google Scholar
• HaradaMTakiMMNoseANon-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrumentJ Autism Dev Disord2011414447454
   Web of Science ®Google Scholar
• EssaMMBraidyNVijayanKRSubashSGuilleminGJExcitotoxicity in the pathogenesis of autismNeurotox Res2013234393400
   PubMed Web of Science ®Google Scholar
• SilvermanJLToluSSBarkanCLCrawleyJNRepetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEPNeuropsychopharmacology201035497698920032969
   PubMed Web of Science ®Google Scholar
• BurketJAHerndonALWinebargerEEJacomeLFDeutschSIComplex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disordersBrain Res Bull2011863–4152158
   PubMed Web of Science ®Google Scholar
• ModiMEYoungLJD-cycloserine facilitates socially reinforced learning in an animal model relevant to autism spectrum disordersBiol Psychiatry2011703298304
   Web of Science ®Google Scholar
• LemonnierEDegrezCPhelepMA randomised controlled trial of bumetanide in the treatment of autism in childrenTransl Psychiatry20122e202
   PubMed Web of Science ®Google Scholar
• EricksonCAPoseyDJStiglerKAMullettJKatschkeARMcDougleCJA retrospective study of memantine in children and adolescents with pervasive developmental disordersPsychopharmacology (Berl)20071911141147
   PubMed Web of Science ®Google Scholar
• NiederhoferHGlutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autismJ Clin Psychopharmacol2007273317318
   PubMed Web of Science ®Google Scholar
• OwleyTSaltJGuterSA prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disordersJ Child Adolesc Psychopharmacol200616551752417069541
   PubMed Web of Science ®Google Scholar
• ChezMGBurtonQDowlingTChangMKhannaPKramerCMemantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerabilityJ Child Neurol2007225574579
   PubMed Web of Science ®Google Scholar
• EricksonCAEarlyMStiglerKAWinkLKMullettJEMcDougleCJAn open-label naturalistic pilot study of acamprosate in youth with autistic disorderJ Child Adolesc Psychopharmacol2011216565569
   PubMed Web of Science ®Google Scholar
• GreenJJHollanderEAutism and oxytocin: new developments in translational approaches to therapeuticsNeurotherapeutics20107325025720643377
   PubMed Web of Science ®Google Scholar
• HollanderENovotnySHanrattyMOxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disordersNeuropsychopharmacology2003281193198
   PubMed Web of Science ®Google Scholar
• HollanderEBartzJChaplinWOxytocin increases retention of social cognition in autismBiol Psychiatry2007614498503
   PubMed Web of Science ®Google Scholar
• AndariEDuhamelJRZallaTHerbrechtELeboyerMSiriguAPromoting social behavior with oxytocin in high-functioning autism spectrum disordersProc Natl Acad Sci U S A2010107943894394
   PubMed Web of Science ®Google Scholar
• TachibanaMKagitani-ShimonoKMohriILong-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disordersJ Child Adolesc Psychopharmacol2013232123127
   PubMed Web of Science ®Google Scholar
• GuastellaAJEinfeldSLGrayKMIntranasal oxytocin improves emotion recognition for youth with autism spectrum disordersBiol Psychiatry2010677692694
   PubMed Web of Science ®Google Scholar
• AnagnostouESooryaLChaplinWIntranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trialMol Autism20123116
   Web of Science ®Google Scholar
• DomesGHeinrichsMKumbierEGrossmannAHauensteinKHerpertzSCEffects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorderBio Psychiatry2013743164171
   PubMed Web of Science ®Google Scholar
• GueriniFRBolognesiEChiappediMHLA polymorphisms in Italian children with autism spectrum disorder: Results of a family based linkage studyJ Neuroimmunol20112301–2135142
   Web of Science ®Google Scholar
• GueriniFRBolognesiEChiappediMActivating KIR molecules and their cognate ligands prevail in children with a diagnosis of ASD and in their mothersBrain Behav Immun2013
   Web of Science ®Google Scholar
• GhezzoAGueriniFRBolognesiENeuropsychological gender differences in healthy individuals and in pediatric neurodevelopmental disorders. A role for SNAP-25Med Hypotheses2009736978980
   Web of Science ®Google Scholar
• GueriniFRBolognesiEChiappediMSNAP-25 single nucleotide polymorphisms are associated with hyperactivity in autism spectrum disordersPharmacol Research2011643283288
   Web of Science ®Google Scholar